Suzhou, October 31, 2025 — The European Society for Medical Oncology Asia Congress (ESMO Asia 2025) will be held in Singapore from December 5-7, 2025. The first-in-human study of NXL-004, an in situ conversion gene therapy for malignant glioma, conducted by the Fourth Affiliated Hospital of Soochow University and NeuExcell Therapeutics, will be presented both online and onsite during the conference.
This marks the world’s first clinical report on in situ conversion gene therapy for malignant glioma, leveraging the pioneering NeuroD1-based reprogramming technology developed by Professor Gong Chen. The study, titled "Safety and Efficacy of AAV-NeuroD1-Based Gene Therapy for Patients with Recurrent Malignant Glioma: A First-In-Human Study," will be delivered by Professor Yulun Huang (Department of Neurosurgery, Fourth Affiliated Hospital of Soochow University, China) in the Developmental Therapeutics session (Abstract #172P).
Key Highlights:
• Safety & Tolerability: Preliminary data confirm NXL-004’s favorable safety profile
• Therapeutic Potential: Encouraging clinical outcome observed, supporting the platform’s applicability for severe brain diseases
Broader Pipeline:
NeuExcell is advancing parallel clinical programs for stroke and Alzheimer’s disease using this in situ conversion platform, aiming to transform treatment paradigms for neurological disorders.
About ESMO Asia:
ESMO Asia is the premier oncology conference in the Asia-Pacific region, convening global experts to disseminate breakthrough research and clinical innovations.
About NeuExcell Therapeutics:
NeuExcell is a clinical-stage biotech company focused on addressing neurodegenerative diseases and CNS injuries. Its core platform reprograms glial cells into functional neurons via in situ conversion approach, targeting conditions including glioblastoma, Alzheimer’s, Parkinson’s, and stroke.